Ampio Pharmaceuticals Inc., of Englewood, Colo., retained Torreya Partners LLC as a financial advisor. The company's lead candidate is Ampion, designed to treat inflammatory conditions.
The Institute for Clinical and Economic Review, of Boston, which has taken suggestions for improving its value assessment framework since June, has published the draft revisions and welcomes public comment through Oct. 11. The final updated framework will be posted Dec. 18 and then applied to all assessments initiated in 2020 and beyond.
Iconic Therapeutics Inc., of South San Francisco, Calif., will provide Novartis AG an option to Iconic's ophthalmology program. Novartis made an up-front payment and an equity investment in Iconic, but further details were not released. Iconic plans to take its anti-tissue factor monoclonal antibody, ICON-4, into the clinic next year.
Innovent Biologics Inc., of Suzhou, China, entered into a licensing agreement with Eli Lilly and Co., of Indianapolis, to develop and commercialize its oxyntomodulin analog, OXM3, in China. OXM3 is a dual GLP-1 and glucagon receptor agonist that enters China as a mid-stage clinical development diabetes compound. Financial terms were not disclosed.
Novelion Therapeutics Inc., of Vancouver, the British Columbia Securities Commission and the Ontario Securities Commission issued a general failure-to-file cease trade order for the company's securities. Novelion is unable to file its quarterly report on form 10-Q for the quarter ended June 30. The order prohibits the trading of Novelion securities in any Canadian jurisdiction in which the company is a reporting issuer.
Pfizer Inc., of New York, will invest an additional $500 million to build a gene therapy manufacturing facility in Sanford, N.C. This facility is in addition to Pfizer's Chapel Hill and Kit Creek, N.C., R&D sites. There are more than 3,600 Pfizer workers in the state, including 650 in Sanford. The Sanford facility is projected to add approximately 300 new jobs.
Snap Bio Inc., of San Diego, along with Biomedical Research of Barcelona, said its lead candidate, SNP-162, overcame disabling drug-resistance in treating recurrent advanced and metastatic liver cancer. SNP-162 is designed to inhibit the growth of liver cancer cell lines that are resistant to Sorafenib, which is FDA-approved for treating inoperable hepatocellular carcinoma.
Swedish Orphan Biovitrum AB, of Stockholm, will sell an FDA priority review voucher to Astrazeneca plc, of Cambridge, U.K., for $95 million cash. The voucher allows for an FDA priority review of a single NDA or BLA. Sobi acquired the voucher as part of its acquisition of emapalumab-related business from Novimmune SA in July.
The Tahir Foundation, of Jakarta, and the Asia Pacific Leaders Malaria Alliance launched M2030, designed to eliminate malaria in Asia by 2030 by uniting international health organizations, consumers and business leaders. All funds raised in Indonesia will support malaria-elimination programs in the country.
Themis Bioscience, of Vienna, and Merck & Co. Inc., of Kenilworth, N.J., entered a research collaboration and license agreement to discover and develop undisclosed vaccine candidates against an undisclosed disease target. Merck will provide research funding and make an equity investment in Themis. Themis could receive development and sales milestones of about $200 million, plus royalties.